DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Grn163l is an investigational drug.
There have been 15 clinical trials for Grn163l. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, Plasma Cell, and Multiple Myeloma. The leading clinical trial sponsors are Geron Corporation, National Cancer Institute (NCI), and Breast Cancer Research Foundation.
There are eight US patents protecting this investigational drug and sixty-two international patents.
Recent Clinical Trials for Grn163l
|A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment||Geron Corporation||Phase 3|
|Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors||National Cancer Institute (NCI)||Phase 2|
|Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors||Children's Oncology Group||Phase 2|
Top disease conditions for Grn163l
Top clinical trial sponsors for Grn163l
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Grn163l||Get Started Free||Method for identification of sensitivity of a patient to telomerase inhibition therapy||Geron Corporation (Menlo Park, CA)||Get Started Free|
|Grn163l||Get Started Free||Combined telomerase inhibitor and gemcitabine for the treatment of cancer||Geron Corporation (Menlo Park, CA)||Get Started Free|
|Grn163l||Get Started Free||Cancer treatment by combined inhibition of proteasome and telomerase activities||Geron Corporation (Menlo Park, CA) Memorial Sloan-Kettering Cancer Center (New York, NY)||Get Started Free|
|Grn163l||Get Started Free||Compounds having anti-adhesive effects on cancer cells||Geron Corporation (Menlo Park, CA) Board of Regents of the University of Texas System (Austin, TX)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Grn163l||Cyprus||CY1117234||2028-10-17||Get Started Free|
|Grn163l||Cyprus||CY1119653||2028-10-17||Get Started Free|
|Grn163l||Denmark||DK2342360||2028-10-17||Get Started Free|
|Grn163l||Denmark||DK3029154||2028-10-17||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|